A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 206 participants.

Also called NCT02554877

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 206 participants (enrolled count) (from the registry)
Sponsor
  • Pfizer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02554877
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02554877. Randomized; double masking; primary purpose treatment. Start 2015-10 (registry gives no type); primary completion 2016-08 (actual). Results posted on 2017-08-07.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
PF-06291874
Intervention (Drug)
Placebo
Lead sponsor
Pfizer (class: industry)

Record details

Record id
cardio:ct-nct02554877
Content hash
d8aae1a18f7b7158545faba0333ad15e209a75aaf53d5dff831d2b7c9037d52e